Physician profile
Nancy M Daniels
NPI 1679664593
$9,892.95
in general payments reported to CMS, 2019-2025
31 companies · $1,349 in 2025
The $1,349 reported for 2025 was more than what 82% of Psychiatric/Mental Health (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $244).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,199 · 2022: $1,751 · 2023: $2,375 · 2024: $2,219 · 2025: $1,349.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,943.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,942.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $838.77 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $835.42 | 2022-2025 | Spravato, Invega Sustenna |
| Axsome Therapeutics, INC. | $822.79 | 2022-2025 | Auvelity, Sunosi |
| Teva Pharmaceuticals USA, INC. | $817.36 | 2021-2025 | Uzedy, Austedo Xr, Austedo |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $804.89 | 2021-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $803.88 | 2021-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $673.28 | 2021-2025 | Rexulti, Abilify Maintena, Nuedexta |
| Takeda Pharmaceuticals U.S.A., INC. | $579.09 | 2021-2025 | Trintellix |
| Almatica Pharma LLC | $499.38 | 2022-2025 | Loreev Xr, Sertraline Hcl |
| Supernus Pharmaceuticals, INC. | $399.68 | 2021-2025 | Qelbree, Qelbree |
| Lundbeck LLC | $396.31 | 2021-2025 | Rexulti, Brintellix, Abilify Maintena |
| Sunovion Pharmaceuticals INC. | $322.13 | 2021-2022 | |
| Corium, LLC | $318.14 | 2022-2024 | Azstarys |
| Alkermes, INC. | $308.95 | 2021-2023 | Lybalvi |
| Eisai INC. | $272.42 | 2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $217.40 | 2022-2025 | Fanapt, Hetlioz |
| Bausch Health US, LLC | $168.55 | 2021-2025 | Aplenzin, Wellbutrin |
| Idorsia Pharmaceuticals US INC | $140.92 | 2022-2024 | Quviviq |
| Uswm, LLC | $113.11 | 2021 | |
| Johnson & Johnson Health Care Systems INC. | $105.00 | 2021 | |
| Merck Sharp & Dohme LLC | $79.58 | 2021-2023 | Belsomra |
| Noven Therapeutics, LLC | $77.74 | 2021-2025 | Xelstrym, Secuado |
| Tris Pharma INC | $74.28 | 2023 | Dyanavel Xr |
| Ironshore Pharmaceuticals INC. | $47.13 | 2022-2024 | |
| Jazz Pharmaceuticals INC. | $44.15 | 2021-2022 | |
| Noven Pharmaceuticals, INC. | $35.00 | 2024 | Xelstrym |
| Biogen, INC. | $28.41 | 2024 | |
| Collegium Pharmaceutical, INC. | $20.90 | 2025 | Jornay Pm |
| Owp Pharmaceuticals, INC. | $16.45 | 2021 | |
| Neuronetics, INC. | $16.13 | 2024 | Neurostar Tms Therapy System |
| Indivior INC. | $15.71 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Daniels listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.